Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in MS, it was used only to treat certain cancers.
Based on findings from these studies, the FDA approved Novantrone in October, 2000 for reducing neurologic disability and/or the frequency of clinical relapses (attacks)